亚急性甲状腺炎诊治新进展

doi:10.16138/j.1673-6087.2024.04.08

摘要/Abstract

摘要：

亚急性甲状腺炎是一种常见的甲状腺炎症性疾病，临床漏诊率和误诊率较高，对患者的生活质量造成负面影响。本文将从发病机制、临床表现、诊断和治疗方面对SAT进行综述，旨在提高临床工作者对该疾病的认知。

关键词: 亚急性甲状腺炎, 自限性疾病, 流行病学, 病毒感染, 生物制剂

Abstract:

Subacute thyroiditis (SAT) is a common thyroid inflammatory disease that is frequently prone to misdiagnosis or underdiagnosis, which impact the quality of life for patients adversely. In this review, we summarize the pathogenesis, clinical manifestations, diagnosis, and treatment of SAT, aiming to improve clinician’s understanding of the disease.

Key words: Subacute thyroiditis, Self-limited disease, Epidemiology, Virus infection, Biological agents

中图分类号:

R581.4

李雅洁, 崔岱. 亚急性甲状腺炎诊治新进展[J]. 内科理论与实践, 2024, 19(04): 259-263.

LI Yajie, CUI Dai. Recent advances in diagnosis and treatment of subacute thyroiditis[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(04): 259-263.

图/表 2

参考文献 41

[1]	Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid, 2016, 26(10):1343-1421. pmid: 27521067
[2]	中华医学会内分泌学分会, 中国医师协会内分泌代谢科医师分会, 中华医学会核医学分会, 等. 中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南[J]. 国际内分泌代谢杂志, 2022, 42(5):401-450.
[3]	Nyulassy S, Hnilica P, Stefanovic J. The HL-A system and subacute thyroiditis[J]. Tissue Antigens, 1975, 6(2):105-106. pmid: 1179407
[4]	Stasiak M, Tymoniuk B, Michalak R, et al. Subacute thyroiditis is associated with HLA-B18:01, -DRB101 and -C*04:01- the significance of the new molecular background[J]. J Clin Med, 2020, 9(2):534.
[5]	Ohsako N, Tamai H, Sudo T, et al. Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing[J]. J Clin Endocrinol Metab, 1995, 80(12):3653-3656.
[6]	Rafiei N, Masoudi M, Jadidi H, et al. The association of subacute thyroiditis with viral diseases[J]. Przegl Epidemiol, 2023, 77(2):136-145.
[7]	Brancatella A, Ricci D, Viola N, et al. Subacute thyroiditis after Sars-COV-2 infection[J]. J Clin Endocrinol Metab, 2020, 105(7):dgaa276.
[8]	Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2):271-280.e8. doi: S0092-8674(20)30229-4 pmid: 32142651
[9]	Li MY, Li L, Zhang Y, et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues[J]. Infect Dis Poverty, 2020, 9(1):45.
[10]	Rotondi M, Coperchini F, Ricci G, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells[J]. J Endocrinol Invest, 2021, 44(5):1085-1090. doi: 10.1007/s40618-020-01436-w pmid: 33025553
[11]	Singh A. Subcellular proteome map of human cells[J]. Nat Methods, 2021, 18(7):713. doi: 10.1038/s41592-021-01213-4 pmid: 34239096
[12]	Koehler VF, Knösel T, Hasmann SE, et al. Thyroidal angiotensin-converting enzyme 2 protein expression and thyroid function tests in patients with COVID-19: results from a retrospective case series and a prospective cohort study[J]. Thyroid, 2023, 33(2):177-185.
[13]	Churilov LP, Normatov MG, Utekhin VJ. Molecular mimicry between SARS-CoV-2 and human endocrinocytes: a prerequisite of post-COVID-19 endocrine autoimmunity?[J]. Pathophysiology, 2022, 29(3):486-494.
[14]	Bragazzi NL, Hejly A, Watad A, et al. ASIA syndrome and endocrine autoimmune disorders[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1):101412.
[15]	Cohen Tervaert JW, Martinez-Lavin M, Jara LJ, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023[J]. Autoimmun Rev, 2023, 22(5):103287.
[16]	Kawashima J, Naoe H, Sasaki Y, et al. A rare case showing subacute thyroiditis-like symptoms with amyloid goiter after anti-tumor necrosis factor therapy[J]. Endocrinol Diabetes Metab Case Rep, 2015,2015:140117.
[17]	Nakagawa J, Fujikawa K, Akagi M, et al. Subacute thyroiditis in a patient with psoriatic arthritis switched from secukinumab to adalimumab: a case report and literature review[J]. Mod Rheumatol Case Rep, 2021, 5(1):36-39.
[18]	Falaschi P, Martocchia A, D’Urso R, et al. Subacute thyroiditis during interferon-alpha therapy for chronic hepatitis C[J]. J Endocrinol Invest, 1997, 20(1):24-28. pmid: 9075068
[19]	Dolkar T, Jitidhar F, Patel MJ, et al. Painless subacute thyroiditis in a patient with acute COVID-19 infection: a transient event[J]. Cureus, 2022, 14(7):e26924.
[20]	Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis[J]. Lancet Diabetes Endocrinol, 2020, 8(9):739-741.
[21]	Stasiak M, Michalak R, Stasiak B, et al. Clinical characteristics of subacute thyroiditis is different than it used to be - current state based on 15 years own material[J]. Neuro Endocrinol Lett, 2019, 39(7):489-495.
[22]	Shekarian A, Fakhrolmobasheri M, Mazaheri-Tehrani S, et al. The prevalence of positive thyroid autoantibodies in patients with subacute thyroiditis: a systematic review and meta-analysis[J]. Endocrine, 2024, 84(1):29-41.
[23]	Alvin Mathew A, Papaly R, Maliakal A, et al. Elevated Graves’ disease-specific thyroid-stimulating immunoglobulin and thyroid stimulating hormone receptor antibody in a patient with subacute thyroiditis[J]. Cureus, 2021, 13(11):e19448.
[24]	Stasiak M, Lewiński A. Strong correlation between HLA and clinical course of subacute thyroiditis-a report of the three siblings[J]. Genes (Basel), 2020, 11(11):1282.
[25]	Stasiak M, Tymoniuk B, Adamczewski Z, et al. Sonographic pattern of subacute thyroiditis is HLA-dependent[J]. Front Endocrinol (Lausanne), 2019,10:3.
[26]	Stasiak M, Tymoniuk B, Stasiak B, et al. The risk of recurrence of subacute thyroiditis is HLA-dependent[J]. Int J Mol Sci, 2019, 20(5):1089.
[27]	Stasiak M, Lewiński A. New aspects in the pathogenesis and management of subacute thyroiditis[J]. Rev Endocr Metab Disord, 2021, 22(4):1027-1039.
[28]	Prakash R, Jayaram G, Singh RP. Follicular thyroid carcinoma masquerading as subacute thyroiditis. Diagnosis using ultrasonography and radionuclide thyroid angiography[J]. Australas Radiol, 1991, 35(2):174-177. pmid: 1930018
[29]	Stasiak M, Michalak R, Lewinski A. Thyroid primary and metastatic malignant tumours of poor prognosis may mimic subacute thyroiditis - time to change the diagnostic criteria: case reports and a review of the literature[J]. BMC Endocr Disord, 2019, 19(1):86. doi: 10.1186/s12902-019-0415-y pmid: 31387553
[30]	Zhang Q, Liao L, Peng Q, et al. Value of contrast-enhanced ultrasound in differentiating clinically atypical subacute thyroiditis from papillary thyroid carcinomas[J]. Ultrasound Med Biol, 2021, 47(12):3384-3392. doi: 10.1016/j.ultrasmedbio.2021.09.001 pmid: 34602283
[31]	Jonklaas J. Infiltration of the thyroid gland by non-thyroid malignancy: a literature review reveals this to be an unusual cause of hyperthyroidism[J]. J Clin Transl Endocrinol, 2020,20:100221.
[32]	Nishihara E, Kudo T, Ito M, et al. Papillary thyroid carcinomas are highly obscured by inflammatory hypoechoic regions caused by subacute thyroiditis: a longitudinal evaluation of 710 patients using ultrasonography[J]. Endocr J, 2020, 67(5):569-574. doi: 10.1507/endocrj.EJ19-0597 pmid: 32062627
[33]	Benbassat CA, Olchovsky D, Tsvetov G, et al. Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005[J]. J Endocrinol Invest, 2007, 30(8):631-635. doi: 10.1007/BF03347442 pmid: 17923793
[34]	Zhang J, Ding G, Li J, et al. Risk factors for subacute thyroiditis recurrence: a systematic review and meta-analysis of cohort studies[J]. Front Endocrinol (Lausanne), 2021,12:783439.
[35]	Hepsen S, Akhanli P, Sencar ME, et al. The evaluation of low- and high-dose steroid treatments in subacute thyroiditis: a retrospective observational study[J]. Endocr Pract, 2021, 27(6):594-600.
[36]	Kubota S, Nishihara E, Kudo T, et al. Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan[J]. Thyroid, 2013, 23(3):269-272. doi: 10.1089/thy.2012.0459 pmid: 23227861
[37]	Zeng J, Jia A, Zhang J, et al. Comparison of the therapeutic effects of 15 mg and 30 mg initial daily prednisolone doses in patients with subacute thyroiditis: a multicenter, randomized, open-label, parallel-controlled trial[J]. Ann Med, 2023, 55(2):2288941.
[38]	Duan L, Feng X, Zhang R, et al. Short-term versus 6-week prednisone in the treatment of subacute thyroiditis: a randomized controlled trial[J]. Endocr Pract, 2020, 26(8):900-908.
[39]	Huo J, Chen C, Gao D, et al. Ultrasound-guided capsular thyroid injection therapy with dexamethasone and lidocaine mixture for subacute thyroiditis: a single-center study[J]. J Ultrasound Med, 2023, 42(3):613-621.
[40]	Yang X, Yang LX, Wu J, et al. Treatment of lidocaine on subacute thyroiditis via restraining inflammatory factor expression and inhibiting pyroptosis pathway[J]. J Cell Biochem, 2019, 120(7):10964-10971. doi: 10.1002/jcb.27675
[41]	Tian Z, Su Y, Zhang M, et al. Successful management of recurrent subacute thyroiditis by adding colchicine to glucocorticoid treatment: a case series study[J]. Horm Metab Res, 2020, 52(10):712-717.

主要标准	次要标准
炎症因子：ESR↑或CRP↑	甲状腺硬性肿胀
甲状腺超声：病灶呈边缘模糊、血流减少的低回声区	甲状腺疼痛和压痛
	FT₄↑，TSH↓
	摄I¹³¹率曲线低平
	FNAC示多核巨细胞、片状上皮样细胞、不同程度炎性细胞

临床特征	具体分级	评分
发热	无	0
	有，最高≤38℃	1
	有，最高>38℃	2
压痛	无	0
	轻度	1
	重度	2
甲状腺肿大（超声或触诊）	无	0
甲状腺肿大（超声或触诊）	有	1
ESR	正常范围	0
	25~60 mm/h	1
	>60 mm/h	2